Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
Rhea-AI Summary
Recursion (NASDAQ: RXRX) announced that on February 6, 2026 its Compensation Committee approved inducement restricted stock unit awards covering 820,431 shares of Class A common stock granted to 17 new employees under the 2024 Inducement Equity Incentive Plan.
Each RSU vests 25% at the first quarterly vesting date on or after the one-year anniversary of the vesting commencement date, then vests at 1/16th each quarter thereafter, subject to continued employment and plan/grant agreement terms. Grants were made pursuant to Nasdaq Listing Rule 5635(c)(4).
Positive
- None.
Negative
- None.
News Market Reaction – RXRX
On the day this news was published, RXRX declined 3.50%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
RXRX fell 3.64% while sector peers were mixed: some up (e.g., GLPG, APGE, TVTX) and others down (e.g., ARQT, IDYA). This pattern points to a stock-specific move rather than a coordinated biotech sector reaction.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 06 | Conference participation | Positive | +4.1% | J.P. Morgan and Needham conference appearances announced with webcast access. |
| Dec 08 | Clinical data update | Positive | +2.3% | Positive Phase 1b/2 REC-4881 TUPELO results in FAP with durable responses. |
| Dec 01 | Webinar announcement | Neutral | -5.8% | Scheduled webinar for upcoming TUPELO REC-4881 clinical data readout. |
| Nov 05 | Earnings and update | Negative | -0.8% | Q3 2025 results with lower revenue, high R&D spend, and net loss disclosed. |
| Nov 05 | Leadership transition | Neutral | -0.8% | CEO transition plan outlining Najat Khan as new CEO and governance changes. |
Recent RXRX news has often been followed by moderate moves, with generally positive clinical and conference updates seeing upward reactions, while neutral or structural announcements sometimes coincided with declines.
Over the last few months, Recursion has combined clinical, strategic, and financial updates. Positive REC-4881 TUPELO data on Dec 8, 2025 and a major healthcare conference appearance on Jan 13, 2026 both saw modest gains. By contrast, a webinar announcement on Dec 1, 2025 and a CEO transition plan and Q3 2025-11-05 updates coincided with slight declines. Today’s inducement RSU awards fit into a pattern of ongoing equity-based compensation amid continued pipeline and corporate developments.
Market Pulse Summary
This announcement details inducement RSU awards covering 820,431 shares for 17 new employees under the 2024 Inducement Equity Incentive Plan, structured to vest over several years and tied to continued employment. It adds to an ongoing cadence of corporate, clinical, and governance updates seen since late 2025. Investors may watch how continued equity-based compensation interacts with RXRX’s share price near its 52-week low, overall insider activity, and upcoming pipeline milestones when assessing longer-term dilution and execution risk.
Key Terms
restricted stock unit (rsu) financial
nasdaq listing rule 5635(c)(4) regulatory
inducement equity incentive plan financial
AI-generated analysis. Not financial advice.
Salt Lake City, Utah, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on February 6, 2026, the Compensation Committee of Recursion's Board of Directors approved the grant of inducement restricted stock unit (RSU) awards covering 820,431 shares of its class A common stock in the aggregate to 17 new employees under Recursion's 2024 Inducement Equity Incentive Plan (the “2024 Plan”). Each award was granted as an inducement material to the employee's commencement of employment with Recursion, or a subsidiary of Recursion, pursuant to Nasdaq Listing Rule 5635(c)(4).
Each inducement RSU award will vest as to
About Recursion
Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously generate one of the world’s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine.
Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Montréal, New York, London, and the Oxford area. Learn more at www.recursion.com, or connect on X and LinkedIn.
Media Contact media@recursion.com Investor Contact investor@recursion.com
FAQ
How many shares did Recursion (RXRX) grant as inducement RSUs on February 6, 2026?
What is the vesting schedule for the RXRX inducement RSU awards granted February 6, 2026?
Why did Recursion (RXRX) grant inducement RSUs under the 2024 Plan on February 6, 2026?
How many employees received inducement RSU awards from Recursion (RXRX) in this grant?
Are Recursion's (RXRX) inducement RSU awards subject to continued employment and plan terms?
